SCHEMBL27248330

SCHEMBL27248330

Cc1cccc(Nc2nc(N3CCN(C)CC3)nc3nccnc23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ SRC P12931 3/20 0.53
▸ JAK2 O60674 2/20 0.50
▸ JAK3 P52333 2/20 0.50
▸ EGFR P00533 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CCNK O75909 1/20 0.48
▸ CCND3 P30281 1/20 0.48
▸ CDK9 P50750 1/20 0.48
▸ CDK6 Q00534 1/20 0.48
▸ HRH4 Q9H3N8 2/20 0.47
▸ HTR2C P28335 5/20 0.47
▸ HTR2A P28223 2/20 0.47
▸ TP53 P04637 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ KHK P50053 1/20 0.46
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27248319 0.88 HRH4 (0.46) L3MBTL1LMNACCND3HRH4HTR2C
SCHEMBL27429695 0.88 HRH4 (0.49) L3MBTL1SMN1; SMN2HRH4HTR2CHTR2A
SCHEMBL27248311 0.86 HPGD (0.58) L3MBTL1JAK2JAK3HRH4HTR2C
SCHEMBL27430034 0.86 HTR2C (0.48) L3MBTL1LMNASMN1; SMN2CCNKCCND3
SCHEMBL27429710 0.86 HTR2C (0.64) SRCSMN1; SMN2CCNKCCND3CDK9
SCHEMBL27430722 0.85 HTR2C (0.44) L3MBTL1SRCSMN1; SMN2HRH4HTR2C
SCHEMBL27248392 0.83 HPGD (0.50) JAK2JAK3HTTSMN1; SMN2CDK9
SCHEMBL27248325 0.83 HPGD (0.54) L3MBTL1JAK2JAK3HRH4HTR2C
SCHEMBL27429988 0.81 HTR2C (0.61) HRH4HTR2CHTR2A
SCHEMBL27430032 0.81 HTR2C (0.60) SRCHRH4HTR2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199624-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CHDI FOUNDATION INC (US) 2024-06-20 — — US disclosed
WO-2024118607-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CHDI FOUNDATION, INC. (US) 2024-06-06 — — WO disclosed
WO-2024118607-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CHDI FOUNDATION, INC. (US) 2024-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199624-A1 COMPOUNDS, COMPOSITIONS, AND METHODS MSH2, KRAS, CHAMP1 L3MBTL1 1129/4885SRC 817/4885JAK2 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback